https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33102 15 mL, mismatch ratio > 1.8, baseline ischemic core < 70 mL, and volume of severely hypoperfused tissue < 100 mL). Patients meeting target mismatch criteria were analyzed as a subgroup to identify whether they had different treatment responses from the pooled group. Results: Of 146 pooled patients, 71 received alteplase and 75 received tenecteplase. Tenecteplase-Treated patients had greater early clinical improvement (median National Institutes of Health Stroke Scale score change: Tenecteplase, 7; alteplase, 2; P=0.018) and less parenchymal hematoma (2 of 75 versus 10 of 71; P=0.02). The pooled group did not show improved patient outcomes when treated with tenecteplase (modified Rankin scale score 0-1: odds ratio, 1.77; 95% confidence interval, 0.89-3.51; P=0.102) compared with alteplase therapy. However, in patients with target mismatch (33 tenecteplase, 35 alteplase), treatment with tenecteplase was associated with greater early clinical improvement (median National Institutes of Health Stroke Scale score change: Tenecteplase, 6; alteplase, 1; P < 0.001) and better late independent recovery (modified Rankin scale score 0-1: odds ratio, 2.33; 95% confidence interval, 1.13-5.94; P=0.032) than those treated with alteplase. Conclusions: Tenecteplase may offer an improved efficacy and safety profile compared with alteplase, benefits possibly exaggerated in patients with baseline computed tomography perfusion-defined target mismatch. Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926. URL: https://www.anzctr.org.au. Unique identifier: ACTRN12608000466347.]]> Wed 19 Jan 2022 15:18:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22674 in-situ occlusive thrombus formation (Folt’s model of ‘physiological’ thrombus). Intravenous tPA was administered 60 minutes post-occlusion (n = 6-7/group). Sustained recanalization rates were 0%, 17%, 67% and 71%, for 0.9, 1.8, 4.5, and 10 mg/kg, respectively. Median time to sustained recanalization onset decreased with increasing dosage. We conclude that 10 mg/kg of tPA is too effective, whereas 0.9 mg/kg is ineffective for lysis of occlusive thrombi formed in situ. Neither dose mimics clinical tPA responses. A dose of 2x the clinical dose is a more appropriate mimic of clinical tPA recanalization in this model.]]> Wed 11 Apr 2018 16:44:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10952 Sat 24 Mar 2018 08:14:15 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10430 Sat 24 Mar 2018 08:13:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10749 Sat 24 Mar 2018 08:08:20 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20950 Sat 24 Mar 2018 08:06:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16967 Sat 24 Mar 2018 07:55:24 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19727 Sat 24 Mar 2018 07:53:44 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:287 Sat 24 Mar 2018 07:42:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28585 Sat 24 Mar 2018 07:37:29 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4781 Sat 24 Mar 2018 07:20:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4662 Sat 24 Mar 2018 07:19:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:4665 Sat 24 Mar 2018 07:19:33 AEDT ]]>